USPTO serial 99646824
POLARIS
Reviewed by CopyMark Law Group
Status 661
- Filing date
- Status date
- Registration date
- —
- Examiner
- HOWARD, CHERYL L
- Law office
- TMEG LAW OFFICE 107
What this means
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
Need help with POLARIS?
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
Current trademark owner
Monitor this mark, or talk with CopyMark about this registration.
Not the owner?
File a new U.S. trademark application, or speak with our attorneys.
Owner
Attorney of record
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
Ben Natter
Ben Natter Haug Partners, LLP745 Fifth AvenueNew York, NY 10151United StatesGoods and services
| Class | Description | Status | First use |
|---|---|---|---|
| 009 | Downloadable software using artificial intelligence for use in the fields of healthcare, biotechnology, and life sciences; Downloadable software using artificial intelligence for analysis of clinical data including histopathology, radiology, genomic, and multi-omics data; Downloadable software using artificial intelligence and machine learning for use with predictive biomarker discovery tools to discover, identify and validate biomarkers; Downloadable software relating to clinical decision support to assist healthcare professionals by offering targeted clinical knowledge, patient information, and other relevant data to support clinical decision-making; Downloadable software for diagnostic purposes to provide solutions for pharmaceutical and biotech companies to support targeted therapies; Downloadable software to optimise drug development and clinical trials including patient recruitment and response prediction; Downloadable artificial intelligence software for clinical data analysis and medical diagnostics; all of the aforementioned software limited to the fields of cancer biology, cancer research, cancer diagnostics or cancer treatment; Downloadable software for processing clinical research, diagnostic support and treatment optimisation in oncology and complex diseases; none of the aforesaid goods relating to data measurement, data analysis or data processing applications for health, wellness, fitness and sports monitors or trackers; none of the aforementioned software for the operation, control, calibration or monitoring of laboratory robots, automated liquid handlers, automatic pipetting workstations, laboratory automation equipment and measurement instruments in biotechnology, diagnostics, pharmaceutical research, process analytics and clinical analytics | ACTIVE | — |
| 042 | Design and development of software featuring artificial intelligence for use in the fields of healthcare, biotechnology, and life sciences; Providing temporary use of non-downloadable software using artificial intelligence for analysis of clinical data including histopathology, radiology, genomic, and multi-omics data; Software as a service (SaaS)featuring artificial intelligence software for use in drug research and development, clinical trials, biomarker research and development, diagnostic testing, clinical testing, and clinical diagnostics; Research and development of software relating to biomarker discovery, identification and validation tools; Research and development of software relating to diagnostic testing, clinical testing and clinical diagnostics; Providing temporary use of non-downloadable software for clinical decision support to assist healthcare professionals in personalised treatment planning; Providing temporary use of non-downloadable software for diagnostic purposes to provide solutions for pharmaceutical and biotech companies to support targeted therapies; Providing temporary use of non-downloadable software to optimise drug development and clinical trials including patient recruitment and response prediction; Providing temporary use of non-downloadable software for medical image processing and analysis; Platform as a service (PaaS) featuring platforms for clinical data analysis, integrated clinical research platforms, diagnostic support systems in oncology, treatment optimization for complex diseases; Providing online non-downloadable computer software platforms for scientific research and clinical diagnostics; Cloud-based software services and proprietary software for clinical data analysis and medical diagnostics accessible to hospitals, diagnostic laboratories, research institutions, and pharmaceutical companies; Consultancy and advisory services relating to all of the aforesaid; all of the aforementioned services limited to the fields of cancer biology, cancer research, cancer diagnostics or cancer treatment; Clinical and scientific research using artificial intelligence in the field of digital pathology namely providing digital oncology solutions; Providing temporary use of non-downloadable software for processing clinical research, diagnostic support and treatment optimisation in oncology and complex diseases; none of the aforesaid services relating to data measurement, data analysis or data processing applications for health, wellness, fitness and sports monitors or trackers; none of the aforementioned services relating to the operation, control, calibration or monitoring of laboratory robots, automated liquid handlers, automatic pipetting workstations, laboratory automation equipment and measurement instruments in biotechnology, diagnostics, pharmaceutical research, process analytics and clinical analytics | ACTIVE | — |
Related trademarks
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
Prosecution history
| Date | Code | Event | What it means |
|---|---|---|---|
| Oct 14, 2026 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Oct 14, 2026 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Oct 14, 2026 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| Sep 9, 2026 | XELG | APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED | — |
| Sep 9, 2026 | XELR | APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED | — |
| Jun 12, 2026 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2026 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 12, 2026 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| Jun 11, 2026 | DOCK | ASSIGNED TO EXAMINER | — |
| Jun 10, 2026 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Feb 11, 2026 | TAEA | TEAS AMENDMENT ENTERED BEFORE ATTORNEY ASSIGNED | — |
| Feb 11, 2026 | PARI | TEAS VOLUNTARY AMENDMENT RECEIVED | — |
| Feb 11, 2026 | MAFR | APPLICATION FILING RECEIPT MAILED | — |
| Feb 11, 2026 | NWAP | NEW APPLICATION ENTERED | — |